Diagnostic Procedures Following Lung Cancer Screens with non-Cancer Abnormalities

Principal Investigator

Name
Lois Lamerato

Institution
Henry Ford Health System

Email
llamera1@hfhs.org

About this CDAS Project

Study
PLCO (Learn more about this study)

Project ID
2006-0315

Initial CDAS Request Approval
Jul 1, 2006

Title
Diagnostic Procedures Following Lung Cancer Screens with non-Cancer Abnormalities

Summary
We propose here to utilize the data base of the Henry Ford Health System (HFHS) to collect information on diagnostic procedures undertaken following all screens among a sample of HFHS Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) subjects enrolled at HFHS. The non-lung cancer outcomes, such as cardiac disease, will be investigated to determine whether participation in a cancer screening trial is associated with a higher medical costs unrelated to lung cancer detection and care.

Aims

1. To determine the rates of various follow-up diagnostic procedures in the periods before and after various screening results, with the emphasis on specific abnormal, not suspicious for lung cancer, findings (e.g., COPD, scarring, cardiac abnormalities). 2. To ascertain whether rates for certain procedures are increased in the period after a given abnormal, not suspicious for lung cancer, screening result as compared to the period after a negative screening result or as compared to the period before the abnormal, not suspicious for lung cancer, screening result. 3. To estimate medical costs in the periods before and after various abnormal, not suspicious for lung cancer, screening results as compared to comparable periods before and after negative screens.